Antigenic Epstein Barr virus polypeptides
AssigneeSanofi
InventorsGary J. Nabel, Chih-Jen Wei, Laura Nguyen, Kurt Swanson, Te-Hui Chou
Life of this patent
Estimating the term…
Abstract
This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.
Claims35
A polypeptide comprising an EBV gL polypeptide, an EBV gH polypeptide, an EBV gp42 polypeptide, and a ferritin, wherein a linker having a length of at least 40 amino acids and less than or equal to 50 amino acids separates the EBV gL polypeptide and the EBV gH polypeptide, and wherein the polypeptide comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs:
- 227-231, or to any one of SEQ ID NOs:
- 241-242 lacking the leader sequence.
A polypeptide comprising an EBV gL polypeptide, an EBV gH polypeptide, an EBV gp42 polypeptide, and a ferritin, wherein a linker having a length of 15 to 60 amino acids separates the EBV gH polypeptide and the EBV gp42 polypeptide, and wherein the polypeptide comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs:
- 227-231, or to any one of SEQ ID NOs:
- 241-242 lacking the leader sequence.
A polypeptide comprising an EBV gL polypeptide, an EBV gH polypeptide, a linker having a length of 15 to 60 amino acids that separates the EBV gL polypeptide and the EBV gH polypeptide, an EBV gp42 polypeptide, a linker having a length of 15 to 60 amino acids that separates the EBV gH polypeptide and the EBV gp42 polypeptide, and a ferritin, wherein the EBV gL polypeptide has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:
- 36, the EBV gH polypeptide has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:
- 37, and the EBV gp42 polypeptide has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:
- 239 or 240.
Dependencies are inferred from the claim text.